Founded
2016
CEO
Khurem Farooq
Founders
Peter Lachmann
David Kavanagh
Andrew Lotery
% Shareholding
54%
Stage
Clinical
Number of employees
160+
Raised in a Series C financing in March 2021
$148m
Clinical trials
3

Unless stated all financials at 30 June 2021

Gyroscope website

Gyroscope is developing gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (dry-AMD).

Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of dry AMD and gene therapy as a mode of sustained treatment delivery. Gyroscope’s gene therapy seeks to treat dry AMD by delivering the target protein in a safe and effective manner using Adeno-Associated Virus (AAV) technology.

AMD, a retinal disease, is the leading cause of irreversible blindness in people aged 50 and older. Today there is no effective treatment for the atrophic, dry, form of the disease the late stage of which is known as geographic atrophy (GA). Through their proprietary delivery system, Gyroscope also have significant surgical device development and surgeon training capabilities.

Investment opportunity

  • Seeking to take application of gene therapy beyond rare diseases to treat dry AMD sub-retinally

Unmet medical need

  • AMD is one of the leading causes of permanent vision impairment for people aged 65 and older with no approved treatments

Market opportunity*

  • Initial population of an estimated 3.5 million people in the US & EU5 with GA, late stage dry AMD

Key risks

  • Highly innovative concept 
  • Biological link to clinical outcome 

 

* Gyroscope analysis

The Gyroscope Therapeutics pipeline

Research Pre-clinical Clinical
  • Dry AMD - HORIZON

  • Dry AMD - EXPLORE

  • Dry AMD - FOCUS

Syncona team

Chris Hollowood

Chris Hollowood

Chris is the Chief Investment Officer of Syncona Investment Management Ltd. He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Freeline, Gyroscope, SwanBio and Purespring and was also previously Chairman of Nightstar, a retinal gene the…
View Chris' biography
Position
Chair
Qualification
PhD
Michael Kyriakides

Michael Kyriakides

Michael Kyriakides is a Partner of Syncona Investment Management Ltd. He works closely with Syncona portfolio companies Freeline Therapeutics and Gyroscope Therapeutics Previously, Michael was a member of the Life Sciences team at L.E.K. Consulting, where he worked in projects for pharmaceutical, biotech and private equity clients. Prior to joining L.E.K. Consulting, he was a clinical project and…
View Michael's biography
Qualification
PhD
Dominic Schmidt

Dominic Schmidt

Dominic is a Partner of Syncona Investment Management Ltd. He is a a Director on the board of Anaveon, and Purespring Therapeutics. Prior to joining Syncona, Dominic worked in the life science practice of strategy consultancy L.E.K Consulting. He received his PhD from the Department of Oncology at the University of Cambridge where he was a Cancer Research UK scholar. He also holds a German Diplom…
View Dominic's biography
Qualification
PhD

Gyroscope Therapeutics leaders and founders

Other gene therapy portfolio companies